1.76

12.82% 0.20

After Hours: 1.75 -0.01 -0.57%

Humacyte Inc (HUMA)

Overview News Price History Option Chain Financials Why HUMA Down? Discussions Forecast

Humacyte Inc stock is traded at $1.76, with a volume of 9.43M. It is up +12.82% in the last 24 hours and up +19.73% over the past month. Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Previous Close:

$1.56

Open:

$1.6

24h Volume:

9.43M

Relative Volume:

1.85

Market Cap:

$279.55M

Revenue:

Net Income/Loss:

$-110.78M

P/E Ratio:

-1.6449

EPS:

-1.07

Net Cash Flow:

$-75.59M

1W Performance:

-29.03%

1M Performance:

+19.73%

6M Performance:

+15.03%

1Y Performance:

-69.28%

1-Day Range:

$1.5914

$1.77

1-Week Range:

$1.55

$1.969

52-Week Range:

$1.15

$6.77

Humacyte Inc Stock (HUMA) Company Profile

Name

Humacyte Inc

Sector

Healthcare (1142)

Industry

Biotechnology (637)

Phone

919-313-9633

Address

2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM

Employee

220

Twitter

Next Earnings Date

2025-03-28

Latest SEC Filings

HUMA's Discussions on Twitter

Compare HUMA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HUMA Humacyte Inc	1.76	292.14M	0	-110.78M	-75.59M	-1.07
VRTX Vertex Pharmaceuticals Inc	407.37	104.55B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	464.95	60.36B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	557.73	59.84B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	799.56	49.07B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	327.03	35.16B	4.56B	-176.77M	225.30M	-1.7177

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-27-25	Initiated	Barclays	Overweight
May-14-25	Resumed	H.C. Wainwright	Buy
Dec-20-24	Reiterated	H.C. Wainwright	Buy
Dec-11-23	Initiated	H.C. Wainwright	Buy
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight
Oct-29-21	Initiated	Cowen	Outperform
Sep-24-21	Initiated	Oppenheimer	Outperform
Sep-22-21	Initiated	BTIG Research	Buy
Sep-16-21	Initiated	Piper Sandler	Overweight

View All

Humacyte Inc Stock (HUMA) Latest News

11:56 AM

Live market analysis of Humacyte Inc. Equity Warrant2025 Risk Factors & AI Powered Market Entry Strategies - newser.com

11:56 AM

11:39 AM

Understanding Humacyte Inc. Equity Warrant’s price movementJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com

11:39 AM

09:54 AM

Should I hold or sell Humacyte Inc. Equity Warrant stock in 20252025 Top Decliners & AI Driven Stock Reports - newser.com

09:54 AM

08:59 AM

Is Humacyte Inc. Equity Warrant forming a bottoming baseGap Down & Fast Moving Stock Watchlists - newser.com

08:59 AM

07:55 AM

Applying sector rotation models to Humacyte Inc. Equity Warrant2025 Price Action Summary & Smart Investment Allocation Tips - newser.com

07:55 AM

04:50 AM

Is Humacyte Inc. stock trading near support levelsBreakout Watch & Low Risk High Win Rate Picks - newser.com

04:50 AM

02:35 AM

Applying chart zones and confluence areas to Humacyte Inc.July 2025 Movers & High Yield Equity Trading Tips - newser.com

02:35 AM

Oct 12, 2025

Using fundamentals and technicals on Humacyte Inc. Equity WarrantEarnings Recap Summary & Risk Managed Investment Entry Signals - newser.com

Oct 12, 2025

Relative strength of Humacyte Inc. in sector analysisMarket Movers & Long-Term Growth Plans - newser.com

Oct 12, 2025

Will Humacyte Inc. stock gain from government policiesJobs Report & Verified Short-Term Plans - newser.com

Oct 12, 2025

Can a trend reversal in Humacyte Inc. Equity Warrant lead to recoveryTrade Entry Summary & Entry Point Strategy Guides - newser.com

Oct 12, 2025

Humacyte (HUMA) Is Down 25.7% After Reporting Strong Symvess Trauma Results and Completing $60M Equity Raise - Yahoo Finance

Oct 12, 2025

Oct 10, 2025

Humacyte shares sink as it announces pricing of $60M direct offering - MSN

Oct 10, 2025

Advanced analytics toolkit walkthrough for Humacyte Inc.Take Profit & Long-Term Capital Growth Strategies - newser.com

Oct 10, 2025

Top chart patterns to watch in Humacyte Inc.Earnings Overview Summary & AI Powered Market Entry Ideas - newser.com

Oct 10, 2025

Building trade automation scripts for Humacyte Inc.July 2025 PreEarnings & Fast Gaining Stock Reports - newser.com

Oct 10, 2025

Real time social sentiment graph for Humacyte Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - newser.com

Oct 10, 2025

Published on: 2025-10-10 04:58:04 - newser.com

Oct 10, 2025

Is Humacyte Inc. stock poised for growthWeekly Trade Report & Safe Capital Growth Plans - newser.com

Oct 10, 2025

Oct 09, 2025

Humacyte Announces $60M Stock and Warrants Offering - MSN

Oct 09, 2025

Published on: 2025-10-09 06:28:01 - newser.com

Oct 09, 2025

Is Humacyte Inc. Equity Warrant stock positioned for digital transformation2025 Retail Activity & Real-Time Volume Triggers - newser.com

Oct 09, 2025

Weiss Ratings Reiterates Sell (E+) Rating for Humacyte (NASDAQ:HUMA) - MarketBeat

Oct 09, 2025

Humacyte, Inc.Common Stock (NQ: - FinancialContent

Oct 09, 2025

Oct 08, 2025

Combat Trauma Study Results Might Change The Case For Investing In Humacyte (HUMA) - simplywall.st

Oct 08, 2025

What analysts say about Humacyte Inc stockRisk Mitigation Techniques & Fast Growing Investment Plans - earlytimes.in

Oct 08, 2025

Oct 07, 2025